Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?

Endocrine. 2023 Apr;80(1):232-233. doi: 10.1007/s12020-022-03294-3. Epub 2023 Jan 6.

Djordje S Popovic^{1

2}, Anca Pantea Stoian³, Nikolaos Papanas⁴

¹ Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, Serbia. pitstop021@gmail.com.
² Medical Faculty, University of Novi Sad, Novi Sad, Serbia. pitstop021@gmail.com.
³ Faculty of Medicine, Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
⁴ Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupoli, Greece.

No abstract available

Keywords: Cardiovascular disease; Chronic kidney disease; Glucagon-like peptide-1 receptor agonists; Type 1 diabetes mellitus.

Publication types